By Billy Candra 
A groundbreaking study by Cambridge researchers, published in The Lancet Oncology, has provided crucial evidence that bilateral salpingo-oophorectomy (BSO) – the surgical removal of the ovaries and fallopian tubes – not only drastically lowers the risk of ovarian cancer but also significantly reduces early mortality and the incidence of secondary cancers among women diagnosed with breast cancer who carry specific BRCA1 and BRCA2 genetic variants. This comprehensive investigation, leveraging extensive electronic health records and national disease registration data, offers profound reassurance to high-risk individuals and their clinicians, while simultaneously highlighting persistent disparities in surgical uptake.
For decades, women identified with pathogenic variants in the BRCA1 and BRCA2 genes have faced a formidable challenge: a substantially elevated lifetime risk of developing breast and ovarian cancers. Prophylactic BSO has long been offered as a risk-reducing strategy for ovarian cancer, given its efficacy in preventing the development of this particularly aggressive and often late-diagnosed malignancy. However, the procedure, by inducing immediate surgical menopause, has also raised concerns about potential long-term adverse health outcomes, including cardiovascular disease, osteoporosis, and neurological effects, particularly for breast cancer survivors for whom hormone replacement therapy (HRT) is often contraindicated. The precise overall impact of BSO on total mortality and the risk of other conditions in this specific cohort remained a critical area of uncertainty.
The Genetic Imperative: Understanding BRCA1 and BRCA2
The BRCA1 and BRCA2 genes are integral components of the human body’s DNA repair machinery. They function as tumor suppressor genes, responsible for repairing damaged DNA and preventing uncontrolled cell growth. When these genes harbor pathogenic variants (mutations), their ability to repair DNA is compromised, leading to an accumulation of genetic errors that can predispose individuals to various cancers.
Women inheriting a pathogenic variant in BRCA1 or BRCA2 face a dramatically increased lifetime risk of developing breast cancer, often at a younger age. For BRCA1 carriers, the lifetime risk of breast cancer can be as high as 70-80%, and for BRCA2 carriers, it can be 60-70%, compared to approximately 13% in the general population. The risk of ovarian cancer is even more starkly elevated, with BRCA1 carriers facing a 40-60% lifetime risk and BRCA2 carriers a 10-20% risk, in contrast to a mere 1-2% in the general female population. These genes also confer increased risks for other cancers, including prostate cancer in men, pancreatic cancer, and melanoma.
The discovery of BRCA1 in 1994 and BRCA2 in 1995 revolutionized cancer genetics, leading to the development of genetic testing and the implementation of personalized risk management strategies. Clinical guidelines subsequently recommended intensive surveillance and prophylactic surgeries for carriers, including prophylactic mastectomy for breast cancer risk reduction and BSO for ovarian cancer risk reduction. The recommendation for BSO typically falls within specific age ranges: between 35 and 40 years for BRCA1 carriers, and between 40 and 45 for BRCA2 carriers, aligning with the observed onset patterns of ovarian cancer in these populations.
Addressing a Critical Clinical Dilemma: The Ethics of Research
Historically, the gold standard for evaluating the effectiveness and safety of medical interventions is the randomized controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention or a control (e.g., no intervention or a placebo), allowing researchers to isolate the effects of the treatment. However, for an intervention like BSO in BRCA1/2 carriers, conducting an RCT presents insurmountable ethical challenges. Randomly assigning high-risk women to a control group that does not receive BSO would knowingly expose them to a significantly increased and preventable risk of developing ovarian cancer, a disease with notoriously poor prognosis. This ethical barrier has long impeded the ability to rigorously assess the full spectrum of BSO’s long-term outcomes, particularly beyond ovarian cancer prevention.
To navigate this ethical conundrum, the Cambridge research team, in collaboration with the National Disease Registration Service (NDRS) in NHS England, adopted an innovative approach. They leveraged the vast repository of routinely collected electronic health records and genetic testing data curated by NDRS. This methodology allowed them to analyze real-world outcomes in a large cohort of women who had already made the decision to undergo BSO or not, based on clinical guidelines and personal choice, thereby circumventing the ethical issues of an RCT. This approach, while not yielding the same level of causal certainty as an RCT, provides robust observational evidence that is highly valuable in clinical decision-making when RCTs are not feasible.
Study Design and Key Findings
The Cambridge study focused on BRCA1 and BRCA2 pathogenic variant carriers who had already been diagnosed with breast cancer. This specific group is particularly vulnerable, as they not only face the elevated risks associated with their genetic predisposition but also contend with the complexities of managing a prior cancer diagnosis, which often restricts options like HRT to mitigate menopausal symptoms.
The researchers identified a cohort of 3,400 women, roughly evenly split between BRCA1 and BRCA2 carriers, all with a history of breast cancer. Of these, approximately 850 BRCA1 carriers and 1,000 BRCA2 carriers had undergone BSO surgery. The team meticulously tracked their long-term health outcomes over a median follow-up period of 5.5 years, a duration substantial enough to observe meaningful differences in survival and disease incidence.
The results were compelling and unequivocally positive:
-
Reduced Early Mortality: Women who underwent BSO were approximately half as likely to die from cancer or any other cause during the follow-up period. This translates to a substantial improvement in overall survival. The benefit was particularly pronounced in BRCA2 carriers, who experienced a 56% reduction in mortality, compared to a 38% reduction in BRCA1 carriers. This differential may reflect variations in the biological aggressiveness of cancers associated with each gene, or possibly different hormonal sensitivities.
-
Lower Risk of Secondary Cancers: Beyond the dramatic reduction in ovarian cancer risk (previously established at 80%), the study revealed that women undergoing BSO also had a roughly 40% lower risk of developing a second primary cancer. This finding is significant, suggesting that the hormonal changes induced by BSO, specifically the removal of ovarian estrogen production, may have a broader protective effect against hormone-sensitive cancers, including new primary breast cancers.
-
No Increased Risk of Adverse Health Outcomes: Crucially, the study found no link between BSO and an increased risk of other long-term health issues often associated with early menopause, such as heart disease, stroke, or depression. This finding directly contrasts with some previous studies conducted in the general population which suggested a potential association between early menopause and increased cardiovascular or mental health risks. The distinction here is critical: for women with BRCA1/2 variants and a history of breast cancer, the benefits of BSO appear to outweigh these generalized risks, or perhaps the underlying genetic predisposition and cancer history modify these associations. This reassurance is particularly vital for women who cannot receive HRT due to their breast cancer history.
Hend Hassan, a PhD student at the Centre for Cancer Genetic Epidemiology, and the study’s first author, articulated the significance of these findings: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes. Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Persistent Disparities in Surgical Uptake
Despite the clear and substantial benefits identified, the study unearthed concerning disparities in the uptake of BSO. The data indicated that most women undergoing BSO were white. Black and Asian women were approximately half as likely to undergo the procedure compared to white women. Furthermore, women residing in less deprived socioeconomic areas were more likely to have BSO than those in the most deprived categories.
These findings underscore a critical public health challenge. Such disparities are often multifactorial, stemming from a complex interplay of socioeconomic barriers, cultural beliefs, access to specialized healthcare, differences in genetic counseling referral patterns, and implicit biases within the healthcare system. Language barriers, lack of awareness about genetic risks, differing perceptions of risk and benefit, and even the availability of culturally competent healthcare providers can all contribute to unequal access to life-saving interventions.
Hassan emphasized the urgency of addressing these inequities: "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women." This calls for targeted public health campaigns, improved access to genetic counseling and testing for all populations, and culturally sensitive patient education to ensure equitable access to informed decision-making and optimal care.
Implications for Clinical Practice and Future Directions
Professor Antonis Antoniou, the study’s senior author and Director of the Cancer Data-Driven Detection programme, highlighted the immediate clinical relevance of the research: "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation." This study provides a powerful evidence base for genetic counselors, oncologists, and gynecologists to confidently recommend BSO, not just as an ovarian cancer preventative measure, but as a procedure that significantly enhances overall survival and reduces the risk of other cancers for breast cancer survivors with BRCA mutations.
The study’s findings are expected to reinforce and potentially strengthen existing clinical guidelines for managing BRCA1/2 carriers. While BSO has been a recognized risk-reduction strategy, the comprehensive demonstration of its impact on overall mortality and secondary cancer risk adds a new dimension to its perceived benefits, particularly for women already grappling with a breast cancer diagnosis. This may lead to more proactive discussions about BSO during initial cancer treatment planning or during follow-up care.
Furthermore, Professor Antoniou underscored the methodological significance: "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." The ability to harness large, high-quality, real-world health data from national registries offers a powerful alternative to traditional RCTs when ethical or practical constraints prevent their execution. This approach is increasingly vital for personalized medicine and understanding long-term outcomes in specific patient populations. The integration of genetic testing data with clinical outcomes is particularly valuable in this context, paving the way for more sophisticated risk prediction models and tailored prevention strategies.
Funding and the Broader Fight Against Cancer
This vital research was made possible through funding from Cancer Research UK, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre. Such investments are critical for advancing our understanding of cancer genetics and developing effective prevention and treatment strategies.
The University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new Cambridge Cancer Research Hospital. This ambitious project, in partnership with Cambridge University Hospitals NHS Foundation Trust, aims to transform cancer diagnosis and treatment for patients across the East of England and beyond. Research conducted at such cutting-edge facilities, like the one highlighted by this study, promises to continue pushing the boundaries of medical science, ultimately changing the lives of countless cancer patients globally. The insights gained from studies like this one underscore the importance of integrating research with clinical care, ensuring that scientific discoveries are rapidly translated into tangible benefits for patients.
In conclusion, the Cambridge study provides compelling evidence that bilateral salpingo-oophorectomy offers substantial, multi-faceted benefits for women with breast cancer who carry BRCA1 and BRCA2 pathogenic variants, significantly improving overall survival and reducing the risk of secondary cancers without increasing other long-term health risks. This crucial finding empowers both patients and clinicians with greater clarity in making informed decisions about this prophylactic surgery, while also issuing a clear call to action to address the persistent disparities in access and uptake, ensuring that all eligible women can benefit from this life-extending intervention.
